IRulya Therapeutics Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IRLA | ALGS | INMB | INDP | TOVX | AIM | |
|---|---|---|---|---|---|---|
| Market cap | 32.21M | 31.35M | 41.18M | 439.70M | 8.72M | 6.42M |
| P/E (TTM) | — | — | — | — | 0.3 | — |
| Forward P/E | -6.8 | -1.0 | -3.1 | -2.4 | -1.0 | -0.4 |
| Price/book | -0.9 | 1.0 | 1.8 | 38.8 | 0.7 | 0.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −89.51% | −29.30% | −18.40% | +25.10% | −29.63% | −90.12% |
| Today | −4.49% | +5.68% | +0.76% | +1.85% | +4.40% | +0.19% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IRLA news ›IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
The Manila Times IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopha
IRulya Therapeutics Inc.: Target Price Consensus and Analysts Recommendations | IRLA | US22053A3059
marketscreener.com Consensus IRulya Therapeutics Inc. Biotechnology & Medical Research Evolution of the Average Target: IRulya Therapeutics Inc. Evolution of the Target Price: IRulya Therapeutics Inc
All Transcripts on IRulya Therapeutics Inc. (IRLA)
Find all the latest transcripts on IRulya Therapeutics Inc. Transcripts IRulya Therapeutics Inc. Biotechnology & Medical Research All financial news and data tailored to specific country editions
More from 1 other outlet
IRulya Therapeutics Inc.: Latest Headlines - Nasdaq Stock Exchange
Find the latest highlights on IRulya Therapeutics Inc. at the Nasdaq stock exchange. Highlights IRulya Therapeutics Inc. Biotechnology & Medical Research All financial news and data tailored to specific country editions
Asset turnover of Quince Therapeutics, Inc. – NASDAQ:IRLA
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes eDSP, developed using their proprietary Autologous Intracellular…
Enterprise value of Quince Therapeutics, Inc. – NASDAQ:IRLA
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes eDSP, developed using their proprietary Autologous Intracellular…
Non-controlling/minority interest of Quince Therapeutics, Inc. – NASDAQ:IRLA
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes eDSP, developed using their proprietary Autologous Intracellular…
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
The company expects its $116 million cash balance to support operations through end-2028 and anticipated Phase 2 clinical readouts. Quince Therapeutics (QNCX) has relaunched as IRulya Therapeutics, focusing on clinical development of…
IRulya Therapeutics Inc.: Official Announcements - Stock Market News
Find the latest press releases and official documents published by IRulya Therapeutics Inc. on MarketScreener. Press Releases IRulya Therapeutics Inc. Biotechnology & Medical Research All financial news and data tailored to specific…
IRulya Therapeutics Inc. : Insider Transactions
Follow insider transactions on IRulya Therapeutics Inc. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions IRulya Therapeutics Inc. Biotechnology & Medical Research Latest…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com10
- tradingview.com6
- cnbc.com1
- globenewswire.com1
- manilatimes.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 20 articles, not a forecast.